Skip to main content
Erschienen in: Medical Oncology 7/2015

01.07.2015 | Original Paper

Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy

verfasst von: Susan Cheraghi, Parsa Nikoofar, Pedram Fadavi, Mohsen Bakhshandeh, Samideh Khoie, Elahe Jazayeri Gharehbagh, Saeid Farahani, Alireza Mohebbi, Maryam Vasheghani, Mahkameh Zare, Alireza Nikoofar, Seied Rabi Mehdi Mahdavi

Erschienen in: Medical Oncology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the risk of sensorineural hearing loss (SNHL) and the relationship between SNHL and radiation dose to the cochlea and frequency range of hearing loss in patients with head and neck cancer. Pure tone audiometry at 250–12,000 Hz was performed on 29 patients diagnosed with head and neck tumours who were treated with 3-dimensional conformal radiation therapy and followed up for 6 months. Paired t test indicated that the mean air conduction threshold before and after radiotherapy was significantly different (paired t test, p < 0.001). SNHL was observed in 15 patients (51 %) according to CTCAE. SNHL increased to 77 % in patients who had received at least five concurrent cisplatin cycles. There was an increased risk of SNHL for ears receiving a mean dose of 5000 cGy compared to those receiving <5000 cGy. SNHL was more severe at higher frequencies of pure tone audiometry in patients with cisplatin-based chemoradiation. The ototoxicity effect of radiation and cisplatin must be considered in the treatment of head and neck tumours. Increasing the dose of cisplatin, radiation dose of cochlea and follow-up interval time may result in increasing severity and frequency of hearing loss incidences. However, characteristic of radiation-induced SNHL seems to be different from chemoradiation-induced SNHL.
Literatur
1.
Zurück zum Zitat Kwong DL, Wei WI, Sham JS, et al. Sensorineural Hearing Loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys. 1996;36(2):281–9.PubMedCrossRef Kwong DL, Wei WI, Sham JS, et al. Sensorineural Hearing Loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys. 1996;36(2):281–9.PubMedCrossRef
2.
Zurück zum Zitat Chen WC, Liao CT, Tsai HC, et al. Radiation-induced hearing impairment in patients treated for malignant parotid tumour. Ann Otol Rhinol Laryngol. 1999;108:1159–64.PubMedCrossRef Chen WC, Liao CT, Tsai HC, et al. Radiation-induced hearing impairment in patients treated for malignant parotid tumour. Ann Otol Rhinol Laryngol. 1999;108:1159–64.PubMedCrossRef
3.
Zurück zum Zitat Pan CC, Eisbruch A, Lee JS, et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2005;61(5):1393–402.PubMedCrossRef Pan CC, Eisbruch A, Lee JS, et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2005;61(5):1393–402.PubMedCrossRef
4.
Zurück zum Zitat Low WK, Toh ST, Wee J, et al. Sensorineural Hearing Loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol. 2006;24(12):1904–9.PubMedCrossRef Low WK, Toh ST, Wee J, et al. Sensorineural Hearing Loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol. 2006;24(12):1904–9.PubMedCrossRef
5.
Zurück zum Zitat Tsan D-L, Lin C-Y, Kang C-J, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012;7(1):215.PubMedCentralPubMedCrossRef Tsan D-L, Lin C-Y, Kang C-J, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012;7(1):215.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Oh Y-T, Kim C-H, Choi J-H, et al. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol. 2004;72(1):79–82.PubMedCrossRef Oh Y-T, Kim C-H, Choi J-H, et al. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol. 2004;72(1):79–82.PubMedCrossRef
7.
Zurück zum Zitat Hitchcock YJ, Tward JD, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to Sensorineural Hearing Loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2009;73(3):779–88.PubMedCrossRef Hitchcock YJ, Tward JD, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to Sensorineural Hearing Loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2009;73(3):779–88.PubMedCrossRef
8.
Zurück zum Zitat Hua C, Bass JK, Khan R, et al. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys. 2008;72(3):892–9.PubMedCrossRef Hua C, Bass JK, Khan R, et al. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys. 2008;72(3):892–9.PubMedCrossRef
9.
Zurück zum Zitat Paulino AC, Lobo M, Teh BS, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010;78(5):1445–50.PubMedCrossRef Paulino AC, Lobo M, Teh BS, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010;78(5):1445–50.PubMedCrossRef
10.
Zurück zum Zitat Chan S, Ng W, Kam K, et al. Sensorineural Hearing Loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys. 2009;73(5):1335–42.PubMedCrossRef Chan S, Ng W, Kam K, et al. Sensorineural Hearing Loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys. 2009;73(5):1335–42.PubMedCrossRef
11.
Zurück zum Zitat Grau C, Moller K, Overgaard M, et al. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991;21(3):723–8.PubMedCrossRef Grau C, Moller K, Overgaard M, et al. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991;21(3):723–8.PubMedCrossRef
12.
Zurück zum Zitat Ho W, Wei W, Kwong D, et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck 1999;21(6):547–53.PubMedCrossRef Ho W, Wei W, Kwong D, et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck 1999;21(6):547–53.PubMedCrossRef
13.
Zurück zum Zitat Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26(10):649–55.PubMedCrossRef Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26(10):649–55.PubMedCrossRef
14.
Zurück zum Zitat Gurney JG, Bass JK. New International Society of Pediatric Oncology Boston ototoxicity grading scale for pediatric oncology: still room for improvement. J Clin Oncol. 2012;30(19):2303–6.PubMedCrossRef Gurney JG, Bass JK. New International Society of Pediatric Oncology Boston ototoxicity grading scale for pediatric oncology: still room for improvement. J Clin Oncol. 2012;30(19):2303–6.PubMedCrossRef
16.
Zurück zum Zitat Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otol Head Neck Surg. 2007;15(5):364–9.CrossRef Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otol Head Neck Surg. 2007;15(5):364–9.CrossRef
17.
Zurück zum Zitat Cardinaal RM, de Groot JC, Huizing EH, et al. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs? Hear Res. 2000;144(1):147–56.PubMedCrossRef Cardinaal RM, de Groot JC, Huizing EH, et al. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs? Hear Res. 2000;144(1):147–56.PubMedCrossRef
18.
Zurück zum Zitat van Ruijven MW, de Groot JC, Smoorenburg GF. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration: a quantitative histological study. Hear Res. 2004;197(1):44–54.PubMedCrossRef van Ruijven MW, de Groot JC, Smoorenburg GF. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration: a quantitative histological study. Hear Res. 2004;197(1):44–54.PubMedCrossRef
19.
Zurück zum Zitat van Ruijven MW, de Groot JC, Klis SF, et al. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005;205(1):241–8.PubMedCrossRef van Ruijven MW, de Groot JC, Klis SF, et al. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005;205(1):241–8.PubMedCrossRef
20.
Zurück zum Zitat Kim H-J, Lee J-H, Kim S-J, et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci. 2010;30(11):3933–46.PubMedCrossRef Kim H-J, Lee J-H, Kim S-J, et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci. 2010;30(11):3933–46.PubMedCrossRef
21.
Zurück zum Zitat Akmansu H, Eryilmaz A, Korkmaz H, et al. Ultrastructural and electrophysiologic changes of rat cochlea after irradiation. Laryngoscope. 2004;114(7):1276–80.PubMedCrossRef Akmansu H, Eryilmaz A, Korkmaz H, et al. Ultrastructural and electrophysiologic changes of rat cochlea after irradiation. Laryngoscope. 2004;114(7):1276–80.PubMedCrossRef
Metadaten
Titel
Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy
verfasst von
Susan Cheraghi
Parsa Nikoofar
Pedram Fadavi
Mohsen Bakhshandeh
Samideh Khoie
Elahe Jazayeri Gharehbagh
Saeid Farahani
Alireza Mohebbi
Maryam Vasheghani
Mahkameh Zare
Alireza Nikoofar
Seied Rabi Mehdi Mahdavi
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 7/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0646-3

Weitere Artikel der Ausgabe 7/2015

Medical Oncology 7/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.